HVRC has recently participated in numerous clinical trials including: ABCD, ACCEPT, ACHIEVE, AFFIRM, ATLAS, CAST, CLOUT, DESTINI, GUSTO, ISIS III, MADIT, RAFT, SCD-HFT, SYMPHONY, SWORD, and TROPHY. HVRC has also taken a leadership role in clinical trials; for example as the coordinating center for a national muticenter clinical trial (ABCD) designed to evaluate arrhythmia risk stratification by ECG T-wave altemans. A clinical trials committee has been established to provide guidance and support for faculty and fellows interested in clinical trials.
Alternans Before Cardioverter Defibrillator Trial
David S. Rosenbaum, M.D. (Principal Investigator), Otto Costantini, M.D., Robert Elston, Ph.D., Katrina Goddard, Ph.D.
HVRC includes a state-of-the-art facility for the prediction and prevention of sudden cardiac death. New and innovative analysis techniques, including T-wave alternans and heart rate variability are being routinely evaluated in clinical and research settings. This research program is closely integrated with basic science studies that investigate the underlying cellular mechanisms of sudden cardiac death. The Alternans Before Cardioverter Defibrillator (ABCD) Trial is an international multi-center clinical trial coordinated by the Heart & Vascular Center at the MetroHealth Campus of Case Western Reserve University. The Heart & Vascular Center also serves as the Core laboratory for the trial. ABCD is designed to develop an innovative approach for preventing and treating sudden cardiac death using the noninvasive T wave alternans test. In addition, a sub-study of this trial is being conducted at MetroHealth to determine a genetic basis for T wave alternans and sudden cardiac death.